Azer Celpresents a potential catalyst in late 2025 with the prospect of a registration trial being granted by the FDA. Swimming in the competitive blood cancer market the recently acquired Imugene Allogeneic therapy needs to shoot the lights out in its Phase 1b study to support conditional registration, and the foundation for a solid Phase 2b/3 Trial.
And today the Phase 1b study does shoot the lights out....Just too good.. The prospect of a registration trial being granted by the FDA improved somewhat in the space of 24 hours.
Here's to the remaining catalysts coming to fruition in 2025 for all long term holders.
Have a good weekend....
IMU Price at posting:
4.3¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)